Politics

Australia Loosens Cannabis Import Rules to Speed Patient Access

Published on February 22, 2017 · Last updated July 28, 2020
Melbourne CBD in Victoria Australia at sunset.

Australian medical cannabis patients and advocates notched a big win this week as the federal government loosened strings on the country’s cannabis-importation laws. The changes will allow overseas suppliers of medicinal cannabis to import into Australia in bulk, store a surplus, and ship directly to patients as doctors prescribe.

Despite progress made in licensing and local cultivation—which became legal in October 2016—patients and doctors have nevertheless found it frustratingly difficult to get a hold of legal cannabis. This is mainly due to the fact that the only products that currently meet quality standards are made overseas and classified in Australia as “unapproved medicines.” In other  words, they have not yet completed rigorous pharmaceutical trials and been approved by government regultors. Instead, medicine must be obtained through complex regulatory pathways such as the Special Access Scheme, which requires individual approvals at both the state and federal levels.

These pathways are not only convoluted from a regulatory perspective, they are expensive. Until now, under the Special Access Scheme, cannabis products were shipped directly from an overseas manufacturer to the patient on a case-by-case basis—a process that entails thousands of dollars in shipping costs alone. Under the changes announced Wednesday, patients will no longer have to have products shipped directly directly from overseas.

According to Federal Health Minister Greg Hunt, the new policy will ensure that there will be sufficient interim supply for “all of the medical demand” among approved patients.

Medical cannabis advocate Lucy Haslam is only cautiously optimistic.

Many see the announcement as long overdue. On local radio last month, even Prime Minister Malcolm Turnbull seemed to acknowledge supply issues when he urged doctors to apply for access to imported medicinal cannabis for seriously ill patients until Australia is in a position to cultivate enough of its own.

Medical cannabis advocate Lucy Haslam, however, is only cautiously optimistic. Halsam, who lost her son to bowel cancer nearly two years ago, says it remains to be seen how quickly patients will be able to get the product in their hands, especially as the application for access can be difficult. Because qualified doctors aren’t allowed to advertise, even finding an authorized prescriber presents a challenge.

For now, the immediate beneficiaries of the change include the existing three foreign suppliers to the Australian market, GW Pharma, Tilray, and Bedrocan, which will now be able to supply medicinal cannabis more efficiently by warehousing it in the country. Also likely to benefit are the existing companies involved in pharmaceutical logistics, stacking the odds even further against local start-ups trying to break into the nascent market. (Editor’s note: Tilray and Leafly are both owned by parent company Privateer Holdings.)

The Australian stock market welcomed the announcement, with Australian-listed cannabis companies such as AusCann (ASX:TWH), MMJ Phytotech (ASX:MMJ) and others posting double-digit gains despite the local businesses not having products currently available for import.

Shop highly rated dispensaries near you

Showing you dispensaries near
See all dispensaries
Leafly Staff
Leafly Staff
Leafly is the world’s largest cannabis information resource, empowering people in legal cannabis markets to learn about the right products for their lifestyle and wellness needs. Our team of cannabis professionals collectively share years of experience in all corners of the market, from growing and retail, to science and medicine, to data and technology.
View Leafly Staff's articles
Get good reads, local deals, and strain spotlights delivered right to your inbox.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.



Stay In Touch

Receive updates on new products, special offers, and industry news.

By providing us with your email address, you agree to Leafly's Terms of Service and Privacy Policy.

Leafly mobile app
Get high for less.
Download the Leafly app.
Download Leafly: Marijuana Reviews on the App Store
Download Leafly Marijuana Reviews on Google Play




* Statements made on this website have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease. Information provided by this website or this company is not a substitute for individual medical advice.


© 2024 Leafly, LLC
Leafly and the Leafly logo are registered trademarks of Leafly, LLC. All Rights Reserved.